Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis

Autor: M, De Vos, O, Dewit, G, D'Haens, F, Baert, F, Fontaine, S, Vermeire, D, Franchimont, T, Moreels, D, Staessen, L, Terriere, B, Vander Cruyssen, E, Louis, Vermeire
Přispěvatelé: AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Male
Time Factors
RELAPSE
Inflammatory bowel disease
Gastroenterology
Feces
FECAL CALPROTECTIN
fluids and secretions
Medicine and Health Sciences
EARLY RESPONSE
Prospective Studies
Young adult
Prospective cohort study
Sigmoidoscopy
Anti-Inflammatory Agents
Non-Steroidal

Remission Induction
Antibodies
Monoclonal

General Medicine
Induction Chemotherapy
Middle Aged
Ulcerative colitis
CROHNS-DISEASE
Treatment Outcome
Disease Progression
Female
medicine.drug
Adult
medicine.medical_specialty
Adolescent
Young Adult
Internal medicine
medicine
Ulcerative Colitis
Humans
LACTOFERRIN
Colitis
Aged
Calprotectin
Dose-Response Relationship
Drug

business.industry
Tumor Necrosis Factor-alpha
medicine.disease
Faecal calprotectin
Infliximab
Surgery
MARKER
Colitis
Ulcerative

Human medicine
business
Leukocyte L1 Antigen Complex
Biomarkers
INFLAMMATORY-BOWEL-DISEASE
Follow-Up Studies
Zdroj: Journal of Crohn s & colitis, 6(5), 557-562. Elsevier
Journal of Crohn's and colitis
JOURNAL OF CROHNS & COLITIS
ISSN: 1873-9946
DOI: 10.1016/j.crohns.2011.11.002
Popis: Aim: To evaluate the effect of infliximab induction therapy on calprotectin levels in patients with ulcerative colitis (UC). Patients and Methods: In this prospective study 53 patients with active UC from 17 centers were treated with infliximab therapy (5 mg/kg) at baseline, week 2, and week 6. Faecal calprotectin was measured every week. Sigmoidoscopies were performed at baseline, week 6 and week 10. Results: Median calprotectin levels decreased from 1260 (IQR 278.5- 3418) at baseline to 72.5 (IQR 18.5 - 463) at week 10 (p
Databáze: OpenAIRE